USPTO aims to fend off Fintiv challenge at SCOTUS

14-11-2023

Muireann Bolger

USPTO aims to fend off Fintiv challenge at SCOTUS

viewimage / Shutterstock.com

Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” | US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”.


review, rule, Fintiv, USPTO, SCOTUS, parallel litigation,Edward Lifesciences, litigation, pharma, arbitrary

LSIPR